Loai Saleh Albinsaad1,2, Jisun Kim2, Il Yong Chung2, Beom Seok Ko2, Hee Jeong Kim2, Jong Won Lee2, Byung Ho Son2, Sei-Hyun Ahn2, Sae Byul Lee3. 1. Department of Surgery, College of Medicine, King Faisal University, Al-Ahsa City, Eastern Province, Saudi Arabia. 2. Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, Korea. 3. Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul, 05505, Korea. newstar153@hanmail.net.
Abstract
PURPOSE: The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. METHODS: We retrospectively reviewed 594 patients diagnosed with stage I-III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups. RESULTS: At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(-)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(-) and 92.1% in the p53(+) group (p = 0.005). BCSS was 96.2% in the p53(-) group and 93% in the p53(+) group (p = 0.008). CONCLUSION: High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.
PURPOSE: The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. METHODS: We retrospectively reviewed 594 patients diagnosed with stage I-III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups. RESULTS: At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(-)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(-) and 92.1% in the p53(+) group (p = 0.005). BCSS was 96.2% in the p53(-) group and 93% in the p53(+) group (p = 0.008). CONCLUSION: High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.
Entities:
Keywords:
Breast neoplasms; Immunohistochemistry; Neoadjuvant therapy; Prognosis; Tumor suppressor protein p53
Authors: Francesco Schettini; Giuseppe Buono; Cinzia Cardalesi; Isacco Desideri; Sabino De Placido; Lucia Del Mastro Journal: Cancer Treat Rev Date: 2016-04-01 Impact factor: 12.111
Authors: P Bertheau; F Plassa; M Espié; E Turpin; A de Roquancourt; M Marty; F Lerebours; Y Beuzard; A Janin; H de Thé Journal: Lancet Date: 2002-09-14 Impact factor: 79.321
Authors: S Beslija; J Bonneterre; H J Burstein; V Cocquyt; M Gnant; V Heinemann; J Jassem; W J Köstler; M Krainer; S Menard; T Petit; L Petruzelka; K Possinger; P Schmid; E Stadtmauer; M Stockler; S Van Belle; C Vogel; N Wilcken; C Wiltschke; C C Zielinski; H Zwierzina Journal: Ann Oncol Date: 2009-07-16 Impact factor: 32.976
Authors: Judy C Boughey; Linda M McCall; Karla V Ballman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa Flippo-Morton; Kelly K Hunt Journal: Ann Surg Date: 2014-10 Impact factor: 12.969
Authors: Reva K Basho; Debora de Melo Gagliato; Naoto T Ueno; Chetna Wathoo; Huiqin Chen; Maryam Shariati; Caimiao Wei; Ricardo H Alvarez; Stacy L Moulder; Aysegul A Sahin; Sinchita Roy-Chowdhuri; Mariana Chavez-MacGregor; Jennifer K Litton; Vincent Valero; Raja Luthra; Jia Zeng; Kenna R Shaw; John Mendelsohn; Gordon B Mills; Debu Tripathy; Funda Meric-Bernstam Journal: Oncotarget Date: 2016-11-22
Authors: Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella Journal: J Cell Mol Med Date: 2008-10-16 Impact factor: 5.310